leadf
logo-loader
viewTRACON Pharmaceuticals

Full interview: TRACON Pharmaceuticals brings on biotech veteran to its board of directors

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the San Diego-based biotech has named Saundra Pelletier, who currently heads up Evofem Biosciences Inc (NASDAQ:EVFM), as a new board director.

Theuer says Pelletier is currently leading that firm's effort to bring Phexxi, a new, non-hormonal contraceptive candidate, to women and will help TRACON with its expected commercial launch of its sarcoma therapy in 2023.

Quick facts: TRACON Pharmaceuticals

Price: 4.81 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $63.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read